398 results match your criteria: "and University of Adelaide[Affiliation]"

Biomimetic Proteoglycans for Intervertebral Disc (IVD) Regeneration.

Biomimetics (Basel)

November 2024

Spine Service & Spine Labs, St George & Sutherland School of Clinical Medicine, Faculty of Health and Medicine, University of New South Wales, Kogarah, NSW 2217, Australia.

Intervertebral disc degeneration, which leads to low back pain, is the most prevalent musculoskeletal condition worldwide, significantly impairing quality of life and imposing substantial socioeconomic burdens on affected individuals. A major impediment to the development of any prospective cell-driven recovery of functional properties in degenerate IVDs is the diminishing IVD cell numbers and viability with ageing which cannot sustain such a recovery process. However, if IVD proteoglycan levels, a major functional component, can be replenished through an orthobiological process which does not rely on cellular or nutritional input, then this may be an effective strategy for the re-attainment of IVD mechanical properties.

View Article and Find Full Text PDF

Background: Up to 65% of patients with chronic myeloid leukemia (CML) who are treated with imatinib do not achieve sustained deep molecular response, which is required to attempt treatment-free remission. Asciminib is the only approved BCR::ABL1 inhibitor that Specifically Targets the ABL Myristoyl Pocket. This unique mechanism of action allows asciminib to be combined with adenosine triphosphate-competitive tyrosine kinase inhibitors to prevent resistance and enhance efficacy.

View Article and Find Full Text PDF

Complex ventricular tachycardias involving the fascicular system (fascicular ventricular tachycardias [FVTs]) can be challenging. In this review, we describe our approach to the diagnosis and ablation of these arrhythmias with 10 illustrative cases that involve (1) differentiation from supraventricular tachycardia; (2) assessment for atypical bundle branch reentry and other interfascicular FVTs; (3) examination of P1/P2 activation sequences in sinus rhythm, pacing, and tachycardia; and (4) entrainment techniques to establish the tachycardia mechanism and aid circuit localization. To summarize, 5 cases had prior ablation with 2 previously misdiagnosed as supraventricular tachycardia.

View Article and Find Full Text PDF

Background: Post-traumatic stress disorder (PTSD) is a serious, debilitating, and prevalent psychiatric condition occurring in people who are traumatized and experience intense, disturbing thoughts and feelings that persist. BNC210 is a novel α7 nicotinic acetylcholine receptor-negative allosteric modulator developed to treat PTSD.

Methods: ATTUNE was a randomized, double-blind, phase 2b, placebo-controlled trial.

View Article and Find Full Text PDF

Background: Fluoropyrimidine (FP) chemotherapies are commonly prescribed for upper and lower gastrointestinal, breast and head and neck malignancies. Over 16,000 people with cancer require FP chemotherapies per annum in Australia. Between 10 and 40% patients experience grade 3-4 (≥ G3) toxicities that require hospital-based management ± intensive care admission.

View Article and Find Full Text PDF
Article Synopsis
  • - The study investigated how season, temperature, and humidity affect the severity of Raynaud phenomenon (RP) in patients with systemic sclerosis, utilizing data from the Australian Scleroderma Cohort Study.
  • - Among 1,972 participants, 26.7% experienced worsened RP related to environmental factors such as low temperatures and high humidity, which were linked to poorer health-related quality of life.
  • - The findings suggest that managing RP may benefit from maintaining warmer and drier conditions, highlighting the importance of environmental factors in treating this condition.
View Article and Find Full Text PDF

Development and Initial Validation of the Novel Scleroderma Clinical Trials Consortium Activity Index.

Arthritis Rheumatol

November 2024

University of Melbourne and St Vincent's Hospital Melbourne, Fitzroy, Victoria, Australia; Sydney Musculoskeletal Research Flagship Centre (University of Sydney), University of Sydney School of Public Health, Sydney, New South Wales, and Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia.

Objective: Accurate measurement of disease activity in systemic sclerosis (SSc) remains a significant clinical challenge. The Scleroderma Clinical Trials Consortium (SCTC) convened an Activity Index (AI) Working Group (WG) to develop a novel measure of disease activity (SCTC-AI).

Methods: Using consensus methodology, we developed a conceptual definition of disease activity.

View Article and Find Full Text PDF

Asciminib in Newly Diagnosed Chronic Myeloid Leukemia.

N Engl J Med

September 2024

From Klinik für Innere Medizin II, Hematology/Oncology, Universitätsklinikum Jena and Comprehensive Cancer Center Central Germany, Campus Jena, Jena (A.H.), and the Department of Oncology and Hematology, Charité-Universitätsmedizin Berlin, Berlin (P.C.) - both in Germany; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China (J.W.); Uijeongbu Eulji Medical Center, Geumo-dong, Uijeongbu-si (D.-W.K.), and the Department of Internal Medicine, Seoul National University Hospital, Biomedical Research Institute, Cancer Research Institute, Seoul National University College of Medicine, Seoul (I.K.) - both in South Korea; Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto (D.D.H.K.); the Department of Internal Medicine, Hematology and Oncology, University Hospital Brno, and Masaryk University - both in Brno, Czech Republic (J.M.); the Department of Hematology, Singapore General Hospital, Singapore (Y.-T.G.); the Department of Hematology, Akita University, Akita City, Japan (N.T.); the Hematology Department, Institut Bergonié, Bordeaux (G.E.), and Novartis Pharma, Paris (S.I.) - both in France; Rocky Mountain Cancer Centers, Boulder, CO (D.A.); the Department of Leukemia, University of Texas M.D. Anderson Cancer Center, Houston (G.C.I.); the University of Chicago, Chicago (R.A.L.); CML Patients Group, CML Advocates Network, Turin, Italy (F.B.); Novartis Pharmaceuticals, East Hanover, NJ (S.K.); Novartis Pharma, Basel, Switzerland (T.M., K.M., L.Y., M.H.); Georgia Cancer Center at Augusta University, Augusta (J.E.C.); and the South Australian Health and Medical Research Institute and University of Adelaide, Adelaide, SA, Australia (T.P.H.).

Article Synopsis
  • * The study included 201 patients receiving asciminib and 204 receiving investigator-selected TKIs, with results showing a higher major molecular response at week 48 for asciminib (67.7%) versus TKIs (49.0%), highlighting its potential advantages.
  • * Asciminib also outperformed imatinib specifically, achieving a major molecular response in 69.3% of patients, compared to 40.2% with imatinib, suggesting it may be
View Article and Find Full Text PDF
Article Synopsis
  • - Asciminib specifically targets the unique myristoyl pocket of BCR::ABL1, proving effective against chronic myeloid leukemia (CML) that has mutations resistant to other treatments, particularly in heavily pretreated patients.
  • - In a phase I study of 48 patients with the T315I mutation, 62.2% reached a BCR::ABL1 level of ≤1% and nearly 49% achieved a major molecular response, demonstrating significant antileukemic activity over a two-year period.
  • - Common severe side effects included increased lipase and low platelet counts, but the overall risk-benefit profile supports asciminib as a viable treatment for T315I-mutated CML-CP
View Article and Find Full Text PDF

Background To improve diabetes management in primary health care for the Aboriginal and Torres Strait Islander peoples population, training programs that are culturally and contextually relevant to the local context are required. Using a scoping review methodology, the aim of this review was to describe the characteristics of chronic disease management training programs for Aboriginal Health Workers and Practitioners, their effectiveness on knowledge and skills, and client-related outcomes, and the enablers, barriers to delivery and participation. Methods Following protocol parameters, a systematic search was conducted in relevant databases and grey literature.

View Article and Find Full Text PDF

Objective: The study objective was to determine the event-free survival (EFS) of Australian patients with diffuse cutaneous systemic sclerosis (dcSSc) who met eligibility criteria for autologous stem cell transplant (ASCT) in previously published randomized controlled trials but were not treated with ASCT.

Methods: Patients who met inclusion criteria for the Autologous Stem Cell Transplantation International Scleroderma (ASTIS) and Scleroderma: Cyclophosphamide Or Transplantation (SCOT) trials were identified from the multicenter Australian Scleroderma Cohort Study (ASCS). EFS (survival without cardiac, renal, or pulmonary failure or death) at 4 years was assessed.

View Article and Find Full Text PDF

Introduction: The outcome of patients with metastatic colorectal cancer (mCRC) has improved significantly in the last few decades. Metastatic colorectal cancer is a highly heterogenous cancer. Beyond second line chemotherapy, treatment decisions are often based on molecular testing.

View Article and Find Full Text PDF

Objective: Patients with pulmonary arterial hypertension (PAH) may be stratified as low, intermediate, or high risk of 1-year mortality. In 2022, the European Society of Cardiology (ESC) updated and simplified its risk stratification tool, based on three variables: World Health Organization functional class, serum N-terminal pro-brain type natriuretic peptide and six-minute walk distance, applied at follow-up visits, intended to guide therapy over time.

Methods: We applied the 2022 ESC risk assessment tool at baseline and follow-up (within 2 years) to a multinational incident cohort of systemic sclerosis-associated PAH (SSc-PAH).

View Article and Find Full Text PDF

Objective: To determine the effect of zoledronic acid (ZA) on the risk of total knee replacement (TKR) in patients with symptomatic knee osteoarthritis and without severe joint space narrowing (JSN).

Methods: We included 222 participants (mean age 62 years, 52% female) from the two-year Zoledronic Acid for Osteoarthritis Knee Pain trial (113 received 5 mg of ZA annually and 109 received placebo) conducted between November 2013 and October 2017. Primary TKR were identified until February 22, 2022.

View Article and Find Full Text PDF

Testosterone and Depression Symptoms in Aging Men.

J Clin Endocrinol Metab

August 2024

Freemasons Centre for Male Health and Wellbeing, South Australian Health and Medical Research Institute, and University of Adelaide, Adelaide, SA 5001, Australia.

View Article and Find Full Text PDF

Methotrexate for juvenile idiopathic arthritis.

Cochrane Database Syst Rev

February 2024

School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia.

Background: Juvenile idiopathic arthritis (JIA) is the most common rheumatic disease in childhood. Methotrexate has broad immunomodulatory properties and is the most commonly used disease-modifying antirheumatic drug (DMARD). This is an update of a 2001 Cochrane review.

View Article and Find Full Text PDF

Objective: To describe the epidemiology, associations, and impact of inflammatory arthritis (IA) in systemic sclerosis (SSc).

Methods: Patients with SSc prospectively enrolled in the Australian Scleroderma Cohort Study were included. IA was defined clinically as the presence of synovitis on examination.

View Article and Find Full Text PDF

The Sjögren's Working Group: The 2023 OMERACT meeting and provisional domain generation.

Semin Arthritis Rheum

April 2024

Department of Rheumatology, National Reference Center for Auto-immune Diseases, Sjogren's ERN Reconnect Center, Assistance Publique-Hôpitaux de Paris, Hôpital Bicêtre, Université Paris-Saclay, INSERM U1184, Le Kremlin Bicêtre, Paris, France.

Article Synopsis
  • Sjögren's disease (SjD) is a complex autoimmune condition characterized by symptoms like dryness, pain, and fatigue, affecting various organ systems in different ways.
  • The variability in symptoms among patients complicates the development of effective treatments, highlighting the need to better understand the disease.
  • In 2023, the OMERACT SjD Working Group held a hybrid meeting to review research and establish core disease domains that reflect both clinical features and patient experiences, ultimately producing a provisional domain list to address SjD's diversity.
View Article and Find Full Text PDF

Structural and electro-anatomical characterization of the equine pulmonary veins: implications for atrial fibrillation.

J Vet Cardiol

April 2024

Department of Veterinary Clinical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Agrovej 8, 2630 Taastrup, Denmark.

Introduction/objectives: Spontaneous pulmonary vein (PV) activity triggers atrial fibrillation (AF) in humans. Although AF frequently occurs in horses, the origin remains unknown. This study investigated the structural and electro-anatomical properties of equine PVs to determine the potential presence of an arrhythmogenic substrate.

View Article and Find Full Text PDF

Background: Many patients with moderately to severely active Crohn's disease do not respond to available therapies or lose response over time. The GALAXI-1 study previously found that three intravenous guselkumab dosages showed superior clinical and endoscopic outcomes over placebo at week 12 in patients with moderately to severely active Crohn's disease. We report the safety and efficacy of subcutaneous guselkumab maintenance regimens to week 48 in the GALAXI-1 study.

View Article and Find Full Text PDF
Article Synopsis
  • The PROTECT trial, a phase 3 study, evaluated the effectiveness of sparsentan, a dual receptor antagonist, in reducing proteinuria compared to irbesartan in patients with immunoglobulin A nephropathy over 110 weeks.* -
  • A total of 406 patients were randomly assigned to either sparsentan or irbesartan, with the primary goal being the change in proteinuria at 36 weeks and secondary goals related to kidney function and safety over the trial duration.* -
  • The findings from the trial, which included a significant reduction in proteinuria with sparsentan, provide important insights into potential treatment strategies for patients with kidney conditions.*
View Article and Find Full Text PDF

Anticipatory anxiety and participation in cancer screening. A systematic review.

Psychooncology

December 2023

Department of Medicine, School of Clinical Sciences, Faculty of Medicine, Nursing and Health Sciences, Monash University, Clayton, Victoria, Australia.

Objectives: To synthesize current evidence on the association between anticipatory anxiety, defined as apprehension-specific negative affect that may be experienced when exposed to potential threat or uncertainty, and cancer screening to better inform strategies to maximize participation rates.

Methods: Searches related to cancer screening and anxiety were conducted in seven electronic databases (APA PsycINFO, Scopus, Web of Science, Embase, Cochrane Library, PubMed, CINAHL), with potentially eligible papers screened in Covidence. Data extraction was conducted independently by multiple authors.

View Article and Find Full Text PDF

Malignancies of upper gastrointestinal tract are aggressive, and most locally advanced unresectable and metastatic cancers are managed by a combination of surgery and neoadjuvant/adjuvant chemotherapy and radiotherapy. Current therapeutic recommendations include targeted therapies based on biomarker expression of an individual tumor. All G/gastro-esophageal junction (GEJ) cancers should be tested for HER2 status as a reflex test at the time of diagnosis.

View Article and Find Full Text PDF

Objective: Regular clinical assessment for complications of systemic sclerosis (SSc) such as pulmonary arterial hypertension (PAH) is essential for early institution of therapy and improved outcomes. The objective of this study was to determine the impact of COVID-19 pandemic-related restrictions on health care access of patients with SSc, including screening for PAH.

Methods: South Australian and Victorian patients enrolled in the Australian Scleroderma Cohort Study were surveyed about their perceptions of the impact of the pandemic on mental well-being, access to medications, investigations, and management of SSc.

View Article and Find Full Text PDF